Literature DB >> 20070494

N-terminal pro B-type natriuretic peptide and left ventricular diameter independently predict mortality in dogs with mitral valve disease.

W Moonarmart1, A Boswood, V Luis Fuentes, D Brodbelt, K Souttar, J Elliott.   

Abstract

OBJECTIVES: To determine whether natriuretic peptide concentrations would predict all cause mortality in dogs with degenerative mitral valve disease.
METHODS: One hundred dogs with naturally occurring degenerative mitral valve disease were prospectively recruited for this longitudinal study. Analysis of outcome was undertaken for 73 dogs for which the outcome was known. Dogs underwent physical examination, electrocardiography and echocardiography. Natriuretic peptide concentrations were measured by Enzyme-linked immunosorbent assay. The ability of natriuretic peptide concentrations, clinical, electrocardiographic and echocardiographic data, to predict all cause mortality was determined using univariable and multivariable Cox proportional hazards analyses.
RESULTS: Thirty dogs died during the period of follow-up. Two variables were independently predictive of all cause mortality; these were the normalised left ventricular end-diastolic diameter and the N-terminal pro B-type natriuretic peptide concentration. An increase of the left ventricular end-diastolic diameter by 0.1 increased the hazard of all cause mortality by 20% (95% confidence interval: 4 to 37%, P=0.01) and a 100 pmol/l increase in N-terminal pro B-type natriuretic peptide increased the hazard by 7% (95 confidence interval: 2 to 11%, P=0.003). CLINICAL SIGNIFICANCE: N-terminal pro B-type natriuretic peptide concentration and left ventricular end-diastolic diameter are significantly and independently predictive of all cause mortality in dogs with degenerative mitral valve disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20070494     DOI: 10.1111/j.1748-5827.2009.00889.x

Source DB:  PubMed          Journal:  J Small Anim Pract        ISSN: 0022-4510            Impact factor:   1.522


  20 in total

1.  Therapeutic effect of low-dose imatinib on pulmonary arterial hypertension in dogs.

Authors:  Shinji Arita; Noboru Arita; Yoshiaki Hikasa
Journal:  Can Vet J       Date:  2013-03       Impact factor: 1.008

2.  The Mitral INsufficiency Echocardiographic score: A severity classification of myxomatous mitral valve disease in dogs.

Authors:  Tommaso Vezzosi; Giovanni Grosso; Rosalba Tognetti; Valentina Meucci; Valentina Patata; Federica Marchesotti; Oriol Domenech
Journal:  J Vet Intern Med       Date:  2021-05-05       Impact factor: 3.333

3.  Comparison of electrocardiographic parameters in dogs with different stages of myxomatous mitral valve disease.

Authors:  Yejin Na; Dohee Lee; Taesik Yun; Yoonhoi Koo; Yeon Chae; Hakhyun Kim; Mhan-Pyo Yang; Byeong-Teck Kang
Journal:  Can J Vet Res       Date:  2021-10       Impact factor: 1.310

4.  Clinical severity score system in dogs with degenerative mitral valve disease.

Authors:  J López-Alvarez; J Elliott; D Pfeiffer; Y-M Chang; M Mattin; W Moonarmart; M J Hezzell; A Boswood
Journal:  J Vet Intern Med       Date:  2015 Mar-Apr       Impact factor: 3.333

Review 5.  Cardiopulmonary and inflammatory biomarkers in heartworm disease.

Authors:  Elena Carretón; Rodrigo Morchón; José Alberto Montoya-Alonso
Journal:  Parasit Vectors       Date:  2017-11-09       Impact factor: 3.876

6.  Vitamin D Status in Different Stages of Disease Severity in Dogs with Chronic Valvular Heart Disease.

Authors:  T Osuga; K Nakamura; T Morita; S Y Lim; K Nisa; N Yokoyama; N Sasaki; K Morishita; H Ohta; M Takiguchi
Journal:  J Vet Intern Med       Date:  2015-08-30       Impact factor: 3.333

7.  Relationship of plasma N-terminal pro-brain natriuretic peptide concentrations to heart failure classification and cause of respiratory distress in dogs using a 2nd generation ELISA assay.

Authors:  P R Fox; M A Oyama; M J Hezzell; J E Rush; T P Nguyenba; T C DeFrancesco; L B Lehmkuhl; H B Kellihan; B Bulmer; S G Gordon; S M Cunningham; J MacGregor; R L Stepien; B Lefbom; D Adin; K Lamb
Journal:  J Vet Intern Med       Date:  2014-10-10       Impact factor: 3.333

8.  Longitudinal electrocardiographic evaluation of dogs with degenerative mitral valve disease.

Authors:  J López-Alvarez; A Boswood; W Moonarmart; M J Hezzell; N Lotter; J Elliott
Journal:  J Vet Intern Med       Date:  2014-02-03       Impact factor: 3.333

9.  Breed differences in natriuretic peptides in healthy dogs.

Authors:  K Sjöstrand; G Wess; I Ljungvall; J Häggström; A-C Merveille; M Wiberg; V Gouni; J Lundgren Willesen; S Hanås; A-S Lequarré; L Mejer Sørensen; J Wolf; L Tiret; M Kierczak; S Forsberg; K McEntee; G Battaille; E Seppälä; K Lindblad-Toh; M Georges; Hannes Lohi; V Chetboul; M Fredholm; K Höglund
Journal:  J Vet Intern Med       Date:  2014-02-03       Impact factor: 3.333

10.  Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.

Authors:  A Boswood; S G Gordon; J Häggström; G Wess; R L Stepien; M A Oyama; B W Keene; J Bonagura; K A MacDonald; M Patteson; S Smith; P R Fox; K Sanderson; R Woolley; V Szatmári; P Menaut; W M Church; M L O'Sullivan; J-P Jaudon; J-G Kresken; J Rush; K A Barrett; S L Rosenthal; A B Saunders; I Ljungvall; M Deinert; E Bomassi; A H Estrada; M J Fernandez Del Palacio; N S Moise; J A Abbott; Y Fujii; A Spier; M W Luethy; R A Santilli; M Uechi; A Tidholm; C Schummer; P Watson
Journal:  J Vet Intern Med       Date:  2017-12-06       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.